is a preclinical contract research organization, serving clients involved in pharmaceutical and nutraceutical R&D, biotechnology, and related sectors. We offer reliable, high quality, and confidential screening services for drug discovery / drug development, characterization of active ingredients, and molecular toxicology.
Roche's investigational therapy for chronic hepatitis C virus infection, R1626, has shown a significant end-of-treatment response rate when given in combination with PEGASYS and COPEGUS.
Schenck Process is the best example of the successes a good strategy process can deliver. In recognition of the successful definition and ongoing realisation of its growth strategy, the Schenck Process Group are delighted to announce that management consults Oliver
DSM Nutritional Products announces a global price increase for all fat soluble vitamins. After recent price increases announced for Vitamin E and A the remaining fat soluble vitamins in the portfolio - K1, Natural Source Vitamin E, Mixed Tocopherols and
KaloBios Pharmaceuticals has completed dosing subjects in a placebo-controlled, single-dose, dose-escalation Phase I clinical trial of its third drug candidate, KB003.
Merck & Co has received a not approvable action letter from the FDA for the company's new drug application for MK-0524A for the treatment of primary hypercholesterolemia or mixed dyslipidemia.
Elixir Pharmaceuticals has announced the issuance of US Patent, which covers the discovery of new and existing chemical entities that modulate the activity of a human sirtuin, SIRT 2.
Teva Pharmaceutical Industries has announced that the FDA has granted approval for the company's abbreviated new drug application to market its epoprostenol, the generic version of GlaxoSmithKline's Flolan for injection.
Pozen has received a total of $20 million in milestone payments from GlaxoSmithKline for the FDA approval of, and Glaxo's intent to commercialize, Treximet for the acute treatment of migraine in adults.
Medical device company NeuroMetrix has received FDA 510(k) clearance for its Advance System. This regulatory determination by the FDA gives NeuroMetrix clearance to market Advance in the US market.
Broadlane announced today that Integrated Healthcare Holdings, Inc. (OTCBB: IHCH) will maintain its exclusive relationship with Broadlane. (PRWeb Apr 29, 2008) Read the full story at http://ww1.prweb.com/releases/Broadlane/IHHI/prweb900224.htm
Sartorius Stedim Biotech and Metroglas have signed an agreement for the exclusive supply of the first disposable integrated electrochemical pH sensors in the market.
InSite Vision has signed a licensing and distribution agreement with Biem Pharmaceuticals, an ophthalmology-focused Turkish pharmaceutical company, for InSite's AzaSite, for the treatment of bacterial conjunctivitis.
North Park Aesthetics has reached an agreement with Biophysica and Interpharma Praha, pursuant to which North Park has acquired exclusive worldwide rights to develop and commercialize products containing fluridil, a novel antiandrogen for topical administration.
NeuroSearch has enrolled and dosed the first patients in a European Phase III study, thereby launching the pivotal clinical program with ACR16 for the treatment of Huntington's disease.
Duska Therapeutics has announced that the company's management and clinical and regulatory consultants met on April 16, 2008, with members of the FDA Division of Cardiovascular and Renal Products to discuss the appropriate regulatory pathway for filing a marketing application
